To quantify more precisely the metabolism of apolipoprotein B (apo B) 
Introduction
Most cholesterol and triglycerides (TG)' in plasma are transported with lipoproteins containing apolipoprotein B (apo B). Two forms of apo B have been identified in humans (1) . One of these, apo B-48, is synthesized in the intestinal mucosa and is associated with chylomicrons. The other, apo B-100, is produced in the liver and is incorporated into TG-rich, very low density lipoproteins (VLDL). In the circulation VLDL undergo lipolytic degradation to smaller lipoproteins-intermediate density lipoproteins (IDL) and low density lipoproteins Dr. Kesaniemi was a visiting scientist on leave from the Second (LDL) (2) . In this sequence, apo B-100 is retained in the lipoprotein particle. The final product, LDL, is cleared from the circulation mainly by LDL receptors (3) . These receptors apparently are specific for apo B-100, although uptake of apo B-containing lipoproteins is facilitated by apolipoprotein E (apo E) which binds tightly to the receptor (4, 5) . Thus, not only is circulating LDL removed by LDL receptors, but intermediate lipoproteins, which contain apo E, also seem to be cleared by the same receptors (5) ; these receptors therefore have been called B-100/E receptors (6) .
A number of isotope kinetic studies have been carried out previously to define the metabolism of apo B-containing lipoproteins. The major technique used to study apo B has been to label isolated VLDL or LDL with radioactive iodine . In a few studies, however, radioactive amino acids have been used as a precursor to apo B (28) (29) (30) . Early investigations that used radioiodinated lipoproteins employed elementary methods for analyzing isotope kinetic data (7-17, 19-21, 25, 26) . Although these investigations have provided useful information about the metabolism of lipoproteins containing apo B, it has become increasingly apparent that a complicated system of metabolic pathways must be taken into consideration to quantify more precisely the kinetics of these lipoproteins. Consequently, kinetic analysis of isotope tracer studies have required increasingly sophisticated approaches, particularly multicompartmental analysis (18, 20-22, 24, 27-30) .
The current study was undertaken to develop a more complete model of apo B kinetics to use as a method for evaluating of apo B metabolism. The experimental basis of this investigation was a series of triple-isotope studies in 14 adult Caucasians and 16 Pima Indians. In these studies VLDL was isolated and labeled with '3'I, and at time of its reinjection, VLDL-TG was labeled endogenously by an intravenous bolus of [3H]glycerol. Furthermore, LDL was isolated, labeled with '25I, and reinjected. The resulting kinetic curves were compared with previous multicompartmental models, and when the data could not be adequately analyzed by using these models, they were modified to conform with both the present experimental data and our current knowledge of lipoprotein metabolism. The final model was then employed as an analytic tool to quantify various pathways of transport of apo B-containing lipoproteins in normal and abnormal states. The results of these latter analyses are presented in the two following articles (31, 32).
Methods
Patients. The patients for this investigation were studied under metabolic ward conditions either in the Special Diagnostic and Treatment Unit of the Veterans Administration Medical Center, San Diego, California, or in the Phoenix Clinical Research Section, National Institutes of Health, Phoenix, Arizona. The characteristics of these patients are described in the following articles (31, 32). A total of 30 patients were studied, most of whom had normal plasma lipids. Informed consent was obtained from each patient.
Study design. The protocol was designed to evaluate the kinetics of VLDL-TG and of apo B in three lipoprotein fractions (VLDL, IDL, and LDL). Three radiolabeled materials were injected. VLDL was isolated ultracentrifugally, and its proteins were labeled with '"'I. LDL also was isolated and labeled with 1251. VLDL-TG was labeled by injection of [2-3H] glycerol as a precursor.
Details of the experimental methods are described in the accompanying articles (31, 32). In brief the patients were maintained on a solid food, isocaloric diet for the duration of the study except for receiving a fat-free diet containing 60% of weight maintenance calories for 36 h before and for 24 h (in Phoenix) or 48 h (in San Diego) after intravenous injection of [3Hlglycerol and '31I-VLDL. The purpose of this regimen was to eliminate an influx of chylomicrons during the period when VLDL metabolism was assessed. VLDL-TG levels remained in steady state during the study. Blood samples were obtained frequently over the postinjection period. 48 h after the VLDL injection, the patients received '251I-LDL, and blood samples were obtained frequently during the following 2 d, and then daily in the fasting state for the next 12-19 d. 24-h urine collections were made for each day of the study. Plasma samples were subjected to sequential ultracentrifugation for isolation of VLDL, IDL, and LDL. TG was extracted from VLDL, and its specific activity was determined. Apo B in VLDL, IDL, and LDL was precipitated with tetramethylurea, or with isopropranol as described recently (33) , and apo B concentrations and specific activities were determined as described in the companion article (31, 32) . Study methods at the two locations were carefully standardized to be comparable, and the isoproponal and tetramethylurea methods were shown to yield identical masses for apo B (33) .
Analysis of data. The above studies gave specific activity-time curves for VLDL-TG, VLDL-apo B (VLDL-B), IDL-B, and LDL-B, and these specific activity data were analyzed by using a multicompartmental modeling procedure developed by Berman and Weiss (34) . Best fits were obtained by using nonlinear regression to minimize the weighted sum of squares (34) . The following criteria were used to determine whether a particular model fit the data. First, previously used models were compared to the current data; if they were qualitatively inconsistent, the model was rejected or changed. Second, a model could be rejected for quantitative inconsistency; for example, the model might predict a mass in a pool that was inconsistent with the measured concentration. Third, a model could be rejected for statistical reasons; if the probability of obtaining the computed results with a particular model was less than a certain tolerance, the model was rejected.
A plasma volume of distribution was calculated from the dilution of 125I-LDL by extrapolation to 0 time of the points obtained during the first 20 min after injection. It was assumed that during this short period no LDL entered the extravascular compartment. The mass of LDL-B in the total plasma compartment was estimated by multiplying the LDL-B concentration by the volume of LDL distribution. The mass of VLDL-B (or IDL-B) in the plasma compartment was assumed to be the product of the VLDL-B (or IDL-B) concentration and the plasma volume computed from the LDL distribution.
Model Development
Subsystem kinetics VLDL-B subsystem. Fig. 1 (18) did not always give the best fit. As shown in Fig. 1 , the shoulder can vary considerably in duration and initial slope. By varying the chain length (number of compartments in the delipidation chain), a good fit could be obtained in all cases. Varying the transport rate through the chain was not sufficient to fit the curves, especially those with very "narrow" shoulders. The selection of the best chain length for each study was made as follows. First, the best fit for a four-compartment chain was obtained by adjusting the values of the parameters to minimize the weighted sum of squares. Inspection of the fit to the shoulder suggested whether a longer or shorter chain should be tried. This process was repeated with the new length until a number was found for which either an increase or a decrease in the number of pools resulted in an increase in the sum of squares (i.e., the sum of squares was minimized with respect to the number of compartments). The length of chain that yielded the minimum sum of squares was taken as the best approximation. Occasionally two or more lengths gave comparable fits. In these cases, all competing lengths were used to simultaneously fit the data for VLDL-B and VLDL-TG (see below). The length that gave the minimum sum of squares for both turnover studies was used for further analyses. 11 Not all chain lengths were analyzed for each turnover. The best length was taken as that for which either an increase or a decrease in n caused an increase in SS.
shows fractional catabolic rates (FCRs) and weighted sums of squares using chains of differing lengths for each of six representative studies. The sums of squares in Table I are normalized to the minimum found for each study. Note that the best length varied from study to study and that the FCR for a given turnover was dependent on the number of pools used, i.e., increasing the chain length decreased the FCR. VLDL-TG subsystem. In the current study, [3H]glycerol was used as a precursor to VLDL-TG. A characteristic radioactivity-time curve for VLDL-TG is shown in Fig. 3 A along with specific activity of VLDL-B for the same study. The VLDL-TG curve has several components: an initial delay followed by a rapid upswing in activity, a flatness of the top of the curve, a rapid downswing, and a slow component (tail). Although early workers attempted to estimate the turnover rates of VLDL-TG from the rate of decline of the rapid downswing, it has become apparent that a more complex analysis is required that takes into account all the components of the curve. Thus, Zech et al. (36) proposed a multicompartmental model for a more thorough analysis of VLDL-TG kinetics ( Fig. 3 B) . This model consists of three subsystems: a two-compartment glycerol subsystem, a TG-synthesis subsystem containing both fast-and slow-synthesis pathways, and a VLDL subsystem, which like the VLDL-B subsystem, contains a rapidly metabolized delipidation chain and a single compartment of more slowly removed VLDL. The glycerol subsystem is required to explain the initial delay before the upswing of radioactivity in plasma VLDL-TG. Published parameters for the glycerol subsystem were used as described in Zech et al. (36) . A fast-synthesis pathway can account for the rapid upswing and rapid decay in radioactivity, but a slow pathway of synthesis is needed to account for the major portion of the tail of the curve. The slowly catabolized VLDL pool also contributes to the tail, as shown by the VLDL-B curve. Finally, a delipidation chain is required to explain the flatness at the top of the curve.
When analyzing the kinetics of VLDL-B and VLDL-TG simultaneously, the following constraints were placed on the system parameters. First, the number of pools in the delipidation chain determined for VLDL-B also was used for the VLDL-TG model. Second, the residence time (and hence the FCR) of TG and apo B in each compartment of the delipidation chain was the same. This indicates that the residence time in a pool is the same for all components of a particle, even though the different components may take different pathways when they leave the pool. That is, from each compartment of the delipidation chain (compartments 1, 6, 7, and 8 in Fig. 3 B), VLDL-TG may have one of two fates. First, it may be removed from the particle via lipase activity or exchange with other lipoproteins; lipolysis is thought to exceed exchange greatly (36). Alternately, it may remain with the particle and continue along the chain. Note that the apo B/TG ratios in the compartments of the delipidation chain are not constant, because TG is removed at each step.
The curves are plotted along with those for VLDL-B. Immediately after the injection of radioiodinated VLDL-B, a small quantity of label always appeared in the 10-min sample of IDL. After a delay, the subsequent IDL curve rose rapidly, crossed the VLDL-B decay curve, and then decayed. In Figure 4 A, the IDL-B curve peaks at -10 h, and the tail remains relatively high at 48 h. In Fig. 4 B, in contrast, the peak occurs at -4 h and decays rapidly thereafter with a low tail.
Very few kinetic studies have been reported previously for the IDL-B fraction. Berman et al. (18) used a single-compartment model for the plasma IDL pool. In most of our studies the IDL-B curve was biphasic, suggesting the existence of two plasma pools, one fast and the other slower. However, the amount of apo B transported through the slow IDL-B compartment was found to be very small, and exclusion of this compartment had a trivial impact on estimated transport rates.
LDL-B subsystem. Fig. 5 presents kinetic curves for radioactivity in plasma and urine after injection of radioiodinated LDL. The plasma curve always showed the typical biphasic decay. The urine curve rose rapidly, peaked at -2 d, and then decayed in parallel with the plasma curve. In some cases, the decay of the urine curve was somewhat faster than the plasma curve. Three models have been suggested for LDL-B kinetics (Fig. 6) ; these models predict different curves. A two-compartment model (38) generally has been employed for LDL-B kinetics (Fig. 6 A) . This model hypothesizes a single intravascular pool in equilibrium with an extravascular pool. Input and output are assumed to be from the intravascular compartment. The plasma decay represents the disappearance of a single homogenous pool of LDL in plasma, and the shape of the curve is determined in large part by the exchange process. The model also predicts the urine radioactivity curve shown in Fig. 6 A.
The second model (Fig. 6 B) are expressed as specific activities. with an extravascular pool. According to this model, the plasma curve for exogenously-labeled LDL-B should have a small shoulder. In patients of the current study, most of whom presumably had "monodisperse" LDL, no shoulder could be identified.
The third model was suggested by Goebel et al. (39) (Fig.  6 C) . These workers proposed two plasma compartments of LDL with different turnover rates. Although these workers did not postulate an exchange pool for the fast compartment, one could exist. Theoretically, the two plasma pools could be differentiated either by observing a third component in the plasma die-away curve or by a urinary curve from deviating that predicted by the two-pool model. A third component in the plasma curve could not be identified in our patients. Furthermore, most of the observed curves of urine radioactivity fit the two-pool model. When deviations occurred, they were in the later part of the urinary curves when the accuracy of counting was less reliable. For these reasons, the current analyses of LDL-B kinetics were based on the two-pool model (Fig. 6 A) . Sources, sizes, and fate of slowly catabolized VLDL pool. The data could not determine whether the slowly metabolized moiety of VLDL was a product of the delipidation chain or of independent synthesis. The origin, however, was of little significance for the overall analysis. Depending on the source, estimates of the pool sizes and transport rates for the slow pool could vary up to 15%, but differences in total transport, chain transport, and FCR of VLDL-B were negligible (<1%).
Subsystem integration
In a few subjects with very high tails for VLDL-B, the amount of '31I-apo B entering LDL appeared to exceed that derived from the fast component of VLDL. This suggested that some of the slowly removed VLDL may have been converted to LDL, and this conversion was allowed. In these patients, allowing the conversion of slow VLDL-B to IDL and LDL also generated a better fit for the peak of the IDL curve. These patients were unusual, however, and the conversion of slowly catabolized VLDL-B to IDL and LDL does not seem appropriate for the general model. IDL-B transport. In some cases, transport of IDL-B appeared to account for all of the transport of apo B from VLDL to LDL. In other patients, this was not the case (Fig. 8) . In this figure, decay curves for VLDL-B, IDL-B, and LDL-B are plotted linearly as fraction of injected dose. The relatively small transport through IDL (d 1.006-1.019 g/dl) is illustrated by the small area under the IDL curve compared to the area under the LDL curve. The larger area under the LDL curve is due in part to the longer residence time of LDL, but the discrepancy between the magnitude of IDL and LDL curves is too great to be explained simply by differences in residence time. The IDL curve is too small to allow for all apo B reaching LDL to pass through the measured IDL pool. The magnitude of the IDL curve that would be required is illustrated by curve A in Fig. 8 .
In those subjects in whom a significant fraction of VLDL-B entered LDL without passing through IDL, a delay between VLDL-B and LDL-B, nevertheless, was observed. This too can be seen in Fig. 8 in which a predicted curve (curve B) for LDL-B (assuming no delay) is compared to the observed appearance of label in LDL. The displacement of the actual curve to the right is indicative of an unexpected slow conversion of VLDL-B to LDL-B. The data thus suggest that a portion of VLDL-B may leave plasma only to reappear several hours later in LDL. This will be considered further in the Discussion section. Interestingly, the delay between VLDL and LDL was approximately equal to the residence time for IDL-B.
Exit of VLDL-B independent ofLDL. When the curves for '31I-LDL-B and '251I-LDL-B were compared, it was noted that VLDL-B usually was not converted quantitatively to LDL (Fig. 9) . When the two curves were normalized to fractions of the injected dose, the area under the '31I-LDL-B curve (derived from VLDL-B) was less than that of 251I-LDL-B (derived from direct injection). This indicates that all 1311-VLDL-B did not reach LDL. The site of removal of apo B before LDL is unknown. It was assumed that VLDL-B exited from the terminal compartment in the chain (Vs), in that mass data for IDL-B suggested this route. However, some exit from IDL cannot be excluded. A small amount of apo B was also removed via the slow compartment of VLDL.
Length of VLDL delipidation chain. Upon integration of the data it was sometimes possible to refine the estimate of the number of compartments in the VLDL chain. The length of the delipidation chain affects the rate of entry of VLDL-B into IDL and LDL. Thus, by combining the data on the shape of the VLDL shoulder and the delays in conversion to IDL and LDL, the length of the chain could be estimated more accurately than from the shoulder alone.
"Direct" input of LDL-B. When the quantity of VLDL-B converted to LDL-B, as calculated from the 13'1-LDL-B curve, was compared to LDL-B transport calculated from 1251I-LDL-B, it was apparent that in many subjects a portion of circulating LDL-B entered plasma without having passed through the Calculation oftransport and production rates Production rates of endogenous material were computed by solution of the mass-balance equations for the compartmental model (40) . Production rates (apo B or TG) into VLDL-B compartments 21 and VI (Fig. 7) were calculated by constraining the sum of masses in compartments VI through V. and 21 to equal the measured VLDL mass. The mass of apo B in compartment 21 was estimated by assuming that all VLDL-B was initially labeled with the same specific activity. As described above, the mass of TG in compartment 21 was assumed to be three times the mass of apo B. The production rate of apo B into LDL compartment LDL4 (Fig. 7) was calculated by constraining the mass in compartment LDLp to equal the measured LDL apo B mass.
Discussion
The integrated model shown in Fig. 7 generally was compatible with the kinetic data from the triple-isotope studies of the present investigations. To be a valid representation of apo B metabolism in humans, however, it should conform to knowledge of metabolism obtained in physiologic studies. Numerous physiologic investigations are consistent with the concept that the liver secretes VLDL, and these lipoproteins in turn are catabolized through IDL to LDL. However, in experimental animals, significant amounts of partially degraded VLDL are cleared from the circulation without conversion to LDL. Most of LDL are removed via LDL receptors, and recently, Goldstein et al. (41) demonstrated in experimental animals that VLDL remnants (including IDL) are cleared by the same receptors. Thus, in animal models, the simplest scheme for metabolism of lipoproteins containing apo B-100 is hepatic secretion of VLDL, lipolysis of VLDL to IDL, conversion of IDL or LDL or removal of some IDL by LDL receptors, and removal of most LDL by LDL receptors (41) (42) (43) .
This scheme (i.e., liver -VLDL -i IDL -LDL, with removal of most LDL and some IDL by LDL receptors) almost certainly represents a fundamental pathway, and can serve as the basis for our model, but the current kinetic data are not entirely consistent with its simplicity. Therefore, modifications of this scheme were required by the observed data, and the following discussion examines these key alterations. VLDL cascade. The above scheme might imply the existence of a single compartment in VLDL; in fact, several previous kinetic studies have employed such a model (9, 11, 25) . Berman et al. (18) , however, have shown this to be an oversimplification. Several types of data support a multicompartment VLDL cascade. The flatness at the top of the VLDL-TG curve and the shoulder on the VLDL-B curve suggest a cascade (18, 36) , as does the delayed rise in activity of IDL-B after injection of labeled VLDL-B. Furthermore, the decay curve for VLDL-TG is steeper than for VLDL-B (Fig. 3) , implying that TG leaves VLDL before whole particles are cleared. Finally, large VLDL have been shown to be precursors of small VLDL (44) (45) (46) . The VLDL cascade presumably results from the progressive removal of triglyceride from the particles. This could occur mostly by lipolysis, but possibly to a small extent by transfer of TG to other lipoproteins; the current data cannot distinguish between these two pathways of TG removal from VLDL, but lipolysis almost certainly predominates (36) .
The existence of a VLDL cascade thus seems inescapable; still this does not mean that all VLDL must pass through the same number of steps of delipidation. The model shown in Fig. 7 restricts apo B entrance to the beginning of the VLDL chain (VI) and exit at the termination (V.). Other models, however, are possible. There could be input or exit at various levels of the cascade; also, the rate of delipidation could decrease at each successive step. We therefore carried out a series of simulations for these different possibilities and compared the simulated results with the model actually used for our analyses. Several statements can be made about these comparisons. First, transport parameters derived from a model with multiple inputs near the beginning of the delipidation chain or with a major input near the end of the chain are very similar to those obtained by using our proposed model that has a changing number of compartments in the delipidation chain. Similarly, parameters derived from a model with a change in rate of delipidation at each step are equivalent to those that use a model with a flexible number of compartments in the chain. The introduction of a variable chain length into the model thus provides a method that basically compensates for multiple inputs or variable lipolytic rates along the cascade, and it gives a better fit to the VLDL curves than a model with a fixed number of compartments. The only situation not accommodated by this model is a significant exit near the beginning of the delipidation chain; in such a case, total VLDL-B transport would be underestimated. Furthermore, removal of apo B from high in the chain could be responsible for the "direct" input of LDL, as discussed below.
"Direct" input ofLDL. Current data and previous reports (25, 27, 42) indicate that total transport of LDL-B can exceed estimated amounts of VLDL-B converted to LDL. This phenomenon suggests that apo B mass can enter LDL "directly," i.e., independent of the VLDL cascade. This extra mass of apo B might reach LDL in one of several ways. Direct secretion of IDL with rapid conversion to LDL is one possibility (46) . Secretion of LDL-sized particles directly into plasma is another, although if such particles are secreted, they must be modified greatly in plasma before becoming typical circulating LDL (47) . Direct input of LDL has been documented in cholesterolfed animals (48-52), but apparently not in normal animals (53) (54) (55) (56) . It has been suggested from studies in humans that employ transplanchic sampling that direct secretion of LDL may occur (57) , but such studies are difficult to interpret. Another mechanism for "direct" input of LDL could be rapid and complete lipolysis of some newly secreted VLDL. A previous study (58) has shown that chylomicron TG undergo lipolysis in a matter of minutes. A similar rapid lipolysis could occur for some VLDL. Such a phenomenon would not be detected in our isotope kinetic data because a pool with rapid entrance and exit from VLDL essentially would be unlabeled. On the basis of studies in normal animals (54-56), we favor this latter mechanism for "direct" input of LDL, although we must stress that our data do not rule out direct hepatic secretion of IDL-or LDL-sized particles in humans.
Role of IDL in apo B transport. (43, 61) and in humans (15, 17, 25, 62) indicate that VLDL remnants, or IDL, can be removed directly from the circulation. Removal of VLDL remnants appears to be mediated by LDL (B-100/E) receptors. Support for this concept comes from studies in patients with homozygous familial hypercholesterolemia and in the Watanabe heritable hyperlipidemic rabbit; in both, the absence of LDL receptors leads to enhanced input of LDL (41, 42) . Varying amounts of VLDL remnants and IDL also might be removed through nonreceptor mechanisms, but whichever the route, the current data bolster the concept of direct removal of VLDL remnants. Although patients with hypertriglyceridemia have been reported previously to have a substantial direct removal of VLDL remnants (1 1, 44, 45) , data of our companion articles (31, 32), as well as data of others (15, 23, 25) , indicate that VLDL-B is not converted quantitatively to LDL, even in normal subjects.
The slow pathway in VLDL. The tail of the VLDL-B curve noted in almost all patients signifies a pool of slowly catabolized VLDL. The size of this pool is greatly increased in type 3 hyperlipoproteinemia (18); this increase results from a structural defect in apo E that interferes with the clearance of VLDL remnants by the liver. In the absence of an apo E defect, only very small quantities of slowly catabolized VLDL are present. Their origin is unknown. In most patients, it was possible to allow direct exit from this compartment, as seemingly occurs in type 3 hyperlipoproteinemia (18) . However, in a few, the pool was somewhat expanded, and it was necessary to transfer its radioactivity to LDL to account for the full conversion of VLDL-B to LDL. Therefore, the metabolism of slow VLDL-B may not be identical in all people.
Model hypothesis. On the basis of our data and current concepts of lipoprotein metabolism, we propose that the scheme presented in Fig. 10 is the best kinetic representation currently available for the metabolism of lipoproteins containing apo B-100. This hypothesis represents an expansion of the model shown in Fig. 7 in that it attempts to reconcile and compartmentalize concepts of lipoprotein metabolism derived from the present data and other physiologic studies. The hypothetical compartments of the model beyond those of Fig.  7 are so designated in Fig. 10 . In this model apo B is assumed to enter a hypothetical compartment (V0), where it can undergo partial lipolysis. Rapid and complete lipolysis in V0 would shunt VLDL-B directly to IDL. This pathway could account for observed "direct" input of unlabeled LDL. Because the rate of entrance and exit from Vo is relatively high, the mass in this compartment in effect is unlabeled. The model also allows for the possibility of direct secretion of IDL by the liver, a possibility that could not be tested in the present study because labeled IDL was not injected. Our hypothesis assumes that no native LDL is secreted directly from the liver.
To the extent that lipolysis is incomplete in V0, VLDL is degraded to the next step of the cascade (Via). Therefore, further studies may require modification of this model for analysis apo B-100 kinetics.
